Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure
Author(s):
Mease, P.; Fleischmann, R.; Wollenhaupt, J.; Deodhar, A.A.; Gladman, D.D.; Hoepken, B.; Peterson, L.; Heijde, D.M. van der
Published
2014
Publication type
Article / Letter to editor
Date issued
2014-10-31
Language
English
Is part of
Arthritis and Rheumatology (2014), Vol. 66, p. S237-S238
